ORIC Oric Pharmaceuticals, Inc.
$12.04▼ -0.25%
Healthcare
Other
After hours
$12.04▲ +0.00%
Sep 11, 7:30 PM ET
Volume 1.06M
Avg Volume (10D) 1.07M
Key Metrics & Fundamentals
Market Cap
$1.25B
P/E Ratio
–
Div Yield
–%
52W Range
7.23 - 14.93
% vs 50 MA
-2.40%
% vs 200 MA
12.79%
RSI-14
40.8
MACD Histogram
-0.2600
Beta (1Y vs SPY)
1.51
Free Cash Flow
-$31.96M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$45.03M
COGS
–
Operating Exp
$45.30M
Operating Income
-$45.30M
EBIT
-$45.30M
Pretax Income
-$41.49M
Net Income
-$41.49M
EPS (Diluted)
-0.38
Price & Volume History
Loading chart…
Recent News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 4, 2026 8:30 PM
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 2, 2026 8:05 PM
Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing
MT Newswires · Aug 28, 2026 8:19 PM
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
Simply Wall St. · Aug 7, 2026 8:15 PM
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
GlobeNewswire · Aug 3, 2026 8:05 PM
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
GlobeNewswire · Jul 20, 2026 12:30 PM
ORIC Pharmaceuticals Starts Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
MT Newswires · Jul 14, 2026 9:07 PM
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
GlobeNewswire · Jul 14, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ORIC's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.